Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2007

View Archived Issues

Novel therapies targeting the prolactin receptor block tumor recurrence in breast cancer models

GEM OS1 Bone Graft begins pivotal study in E.U.

ARCA's Series B financing to support regulatory filing of bucindolol

Melanoma-specific CD8+ T-cell responses seen with melanoma pharmaccine

Snapshots on cancer immunotherapy

HDAC inhibitors promote memory consolidation via activation of CREB-mediated gene transcription

Snapshots of preclinical studies in hematology

Proellex shows superior efficacy and safety in endometriosis compared to Lucrin

Enrollment completed in phase II trial of Huperzine A

Enrollment open in U.K. study of Reolysin with gemcitabine in advanced cancers

New phase I study for terameprocol in solid tumors

OT-551 studied in phase II trial for geographic atrophy

NRC-IRAP contribution to support development of WBI-2100

Coley acquires 3M's therapeutic Toll-like receptor R&D programs

Recent patents describe new treatment options for endocrine disorders

Novel antiinfective agents disclosed in recent patent literature

New therapeutic options for cancer imparted in recent patents

Gabapentin GR begins phase II trial for menopausal hot flashes

Valopicitabine triple combination therapy shows good HCV RNA clearance rates

U.S. orphan drug designation for Multikine

Immtech grants U.S. commercialization rights to Par for pafuramidine

Pfizer's anti-IGF-IR antibody shows clinical benefit as a single agent

Phase II data on picoplatin disclosed

Pazopanib shows activity in mRCC and ovarian cancer

Astion obtains extra capital to accelerate phase III for ASF-1096

Favrille acquires anti-CD20 monoclonal antibodies from Diversa

SPA agreement for phase III trial of Xanafide in secondary AML

Elestrin launched in U.S.

FDA Advisory Committee recommends against approval of rimonabant

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...